'Betydelig usikkerhed': Systematisk gennemgang finder ingen pålidelig evidens for fordelene ved pubertetsblokkere

Pubertetsblokkere for kønsdysfori hos unge: En systematisk gennemgang og metaanalyse

Authors
Anna Miroshnychenko, Yetiani Roldan, Sara Ibrahim, Chan Kulatunga-Moruzi, Steven Montante, Rachel Couban, Gordon Guyatt, Romina Brignardello-Petersen
Journal
Archives of Disease in Childhood
Year
2025

Summary

This review collected every study it could find, up to September 2023, on puberty blockers for young people with gender distress, and rated how trustworthy the evidence was. Only 10 studies qualified, and none was a randomised trial, where people are assigned to treatment by chance. The studies were small and often missing results for many people. Every result on mental health, gender distress and bone density was rated very low quality. Bone density seemed lower after treatment, and nearly all young people went on to cross-sex hormones. The authors conclude we cannot tell whether blockers help or harm, and call for better studies. Its findings match other independent reviews, including those for England's Cass Review. But it was funded by SEGM, a group critical of youth transition, it only searched English-language studies, and it misses newer studies.

Key findings

  • Gennemgangen fandt 10 studier: 3 sammenlignede unge, der tog blokkere, med dem, der ikke gjorde, og 7 målte kun de samme personer før og efter.
  • Der var ingen randomiserede forsøg, hvor folk tildeles behandling ved lodtrækning.
  • Al evidens om kønslidelse, daglig funktion og depression blev vurderet som af meget lav kvalitet, så hverken gavn eller skade kan udelukkes.
  • I sammenligningsstudierne så scorerne for daglig funktion noget bedre ud med blokkere efter 12 måneder, men resultatet var så usikkert, at det kunne betyde alt fra lidt dårligere til meget bedre.
  • Knogletætheden i hofte og rygsøjle sakkede bagud i forhold til jævnaldrende efter blokkere, selvom også denne evidens blev vurderet som meget svag.
  • I to studier gik 92 % af de unge, der fik blokkere, videre til krydskønshormoner inden for 1 til 3 år.
  • Flere studier havde resultater for under halvdelen af de unge, og ingen tog ordentligt højde for terapi, andre psykiske tilstande eller støtte fra familien.
  • Forfatterne opfordrer til omhyggelige studier, der følger unge fremad i tid, og, hvis det er etisk, randomiserede forsøg.

Abstract

Aim Gender dysphoria (GD) refers to the psychological distress associated with the incongruence between one's sex and one's gender identity. To manage GD, individuals may delay the development of primary and secondary sex characteristics with the use of puberty blockers. In this systematic review, we assess and summarise the certainty of the evidence about the effects of puberty blockers in individuals experiencing GD. Methods We searched Medline, Embase, PsychINFO, Social Sciences Abstracts, LGBTQ+ Source and Sociological Abstracts from inception to September 2023. We included observational studies comparing puberty blockers with no puberty blockers in individuals aged <26 years experiencing GD, as well as before-after and case series studies. Outcomes of interest included psychological and physical outcomes. Pairs of reviewers independently screened articles, abstracted data and assessed risk of bias. We performed a meta-analysis and assessed the certainty of a non-zero effect using the grading of recommendations assessment, development and evaluation (GRADE) approach. Results We included 10 studies. Comparative observational studies (n=3), comparing puberty blockers versus no puberty blockers, provided very low certainty of evidence on the outcomes of global function and depression. Before-after studies (n=7) provided very low certainty of evidence addressing gender dysphoria, global function, depression, and bone mineral density. Conclusions There remains considerable uncertainty regarding the effects of puberty blockers in individuals experiencing GD. Methodologically rigorous prospective studies are needed to understand the effects of this intervention. Trial registration number PROSPERO CRD42023452171.

Conclusion

The best available evidence reporting the effects of puberty blockers in individuals with GD was mostly very low certainty and therefore we cannot exclude the possibility of benefit or harm. There was evidence available for the outcomes of global function, depression, GD, bone mineral density and progression to gender affirming hormone therapy. High certainty evidence from prospective cohort studies and, if ethical, RCTs, is needed to understand the short and long term effects of puberty blockers in individuals experiencing GD.